Statin Safety: An Overview and Assessment of the Data-2005

American Journal of Cardiology

Volumn 97, Issue 8 SUPPL. 1, 2006, Pages

  Bays, Harold ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MUSCLE ENZYME; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE HEPATITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEMENTIA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENZYME DEFECT; EVIDENCE BASED MEDICINE; FATTY LIVER; HEMATURIA; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; LIVER TOXICITY; MEMORY DISORDER; META ANALYSIS; METABOLIC ACIDOSIS; MONOTHERAPY; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

ANTILIPEMIC AGENTS; CEREBROVASCULAR ACCIDENT; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LIVER; LIVER DISEASES; MUSCULAR DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEINURIA;

EID: 33645853175     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.12.006     Document Type: Article

References (212)

1. Black D.M. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep 4 (2002) 34-41
2. Bays H., and Stein E.A. Pharmacotherapy for dyslipidaemia-current therapies and future agents. Expert Opin Pharmacother 4 (2003) 1901-1938
3. Ballantyne C.M., Corsini A., Davidson M.H., Holdaas H., Jacobson T.A., Leitersdorf E., Marz W., Reckless J.P., and Stein E.A. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
4. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
5. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
6. Ucar M., Mjorndal T., and Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22 (2000) 441-457
7. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
8. Psaty B.M., Furberg C.D., Ray W.A., and Weiss N.S. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. use of cerivastatin and risk of rhabdomyolysis. JAMA 292 (2004) 2622-2631
9. Davidson M.H. Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf 1 (2002) 207-212
10. Evans M., and Rees A. The myotoxicity of statins. Curr Opin Lipidol 13 (2002) 415-420
11. Bottorff M.B. Safety and statins. pharmacologic and clinical perspectives. Am J Manag Care 4 suppl 2 (2004) S27-S37
12. Grundy S.M. Can statins cause chronic low-grade myopathy [editorial]?. Ann Intern Med 137 (2002) 617-618
13. Grundy S.M. The issue of statin safety. where do we stand [editorial]?. Circulation 111 (2005) 3016-3019
14. Strom B.L. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. a counterpoint. JAMA 292 (2004) 2643-2646
15. Piorkowski Jr. J.D. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions. use of cerivastatin and risk of rhabdomyolysis.". JAMA 292 (2004) 2655-2657
16. Andrade S.E., Graham D.J., Staffa J.A., Schech S.D., Shatin D., La G.L., Goodman M.J., Platt R., Gurwitz J.H., and Chan K.A. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol 58 (2005) 171-174
17. American Diabetes Association. Position Statement. Standards of Medical Care in Diabetes [American Diabetes Association Clinical Practice Recommendation]. Diabetes Care 28 suppl 1 (2005) S4-S36
18. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567-572
19. Bays HE. Combination lipid-altering drug therapy with statins: an update [slide talk]. [Lipids Online Website.] Available at: http://www.lipidsonline.org/slides/talk_cme_activity.cfm?tk=33&cme_activityid=94&cmepage=cme_info. Accessed February 6, 2006.
20. Gabow P.A., Kaehny W.D., and Kelleher S.P. The spectrum of rhabdomyolysis. Medicine (Baltimore) 61 (1982) 141-152
21. FDA Advisory Committee Meeting. CRESTOR (ZD4522, rosuvastatin calcium) TABLETS. Briefing Document NDA 21-366 for the Use of CRESTOR (2003). http://www.fda.gov/ohrms/dockets/ac/03/briefing/3968B1_02_A-FDA-Clinical%20Review.pdf June 11, [US Food and Drug Administration Website.] http://www.fda.gov/ohrms/dockets/ac/03/briefing/3968B1_02_A-FDA-Clinical%20Review.pdf. Accessed February 6, 2006.
22. US Food and Drug Administration. Alert for Healthcare Professional. Crestor (Rosuvastatin Calcium) (2005). http://www.fda.gov/cder/drug/InfoSheets/HCP/RosuvastatinHCP.htm [US Food and Drug Administration Website.] United States Department of Health and Human Services, Center for Drug Evaluation and Research March. http://www.fda.gov/cder/drug/InfoSheets/HCP/RosuvastatinHCP.htm. Accessed February 6, 2006.
23. Jamal S.M., Eisenberg M.J., and Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147 (2004) 956-965
24. Tomlinson S.S., and Mangione K.K. Potential adverse effects of statins on muscle. Phys Ther 85 (2005) 459-465
25. Nissen S.E. High-dose statins in acute coronary syndromes. not just lipid levels. JAMA 292 (2004) 1365-1367
26. Mitchel Y.B. High-dose statins in acute coronary syndromes. JAMA 293 (2005) 37-39
27. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., and Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 (2003) 152-160
28. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Lin J.H., Pearson P.G., and Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301 (2002) 1042-1051
29. Evans M., and Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle. are all statins the same?. Drug Saf 25 (2002) 649-663
30. Bays H., and Dujovne C. Colesevelam HCl. a non-systemic lipid-altering drug. Expert Opin Pharmacother 4 (2003) 779-790
31. Bays H.E., Dujovne C.A., McGovern M.E., White T.E., Kashyap M.L., Hutcheson A.G., and Crouse J.R. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 91 (2003) 667-672
32. Bays H.E. Extended-release niacin / lovastatin. the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2 (2004) 485-501
33. Bays H. Trial finds that simvastatin plus niacin is safe in people with coronary artery disease and low HDL cholesterol [commentary]. Evidence-Based Cardiovascular Medicine 8 (2004) 173-176
34. Davidson M.H. Combination therapy for dyslipidemia. safety and regulatory considerations. Am J Cardiol 90 suppl 10B (2002) 50K-60K
35. Reaven P., and Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 109 (1988) 597-598
36. Guyton J.R., and Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 82 suppl 12A (1998) 82U-84U
37. Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 94 (2004) 306-311
38. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., Toth P.D., Favrot L.K., Kerzner B., Nash S.D., Bays H.E., and Simmons P.D. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89 (2002) 672-678
39. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin. analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311 (2004) 228-236
40. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
41. Martin P.D., Dane A.L., Schneck D.W., and Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 25 (2003) 459-471
42. Ellen R.L., and McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 81 suppl 4A (1998) 60B-65B
43. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
44. Rosenson R.S. Statins and the risk of rhabdomyolysis [editorial]. J Endocrinol Invest 25 (2002) 577
45. Davidson M.H., Bays H., Rhyne J., Stein E., Rotenberg K., and Doyle R. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome. an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 27 (2005) 1-13
46. Tricor [fenofibrate] prescribing information (2004), Abbott Laboratories, North Chicago, IL. http://rxabbott.com/pdf/tricorpi.pdf Available at: http://rxabbott.com/pdf/tricorpi.pdf. Accessed February 6, 2006.
47. Bays H.E., Ose L., Fraser N., Tribble D.L., Quinto K., Reyes R., Johnson-Levonas A.O., Sapre A., and Donahue S.R. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
48. Phillips P.S. Ezetimibe and statin-associated myopathy [letter]. Ann Intern Med 19 141 (2004) 649
49. Fux R., Morike K., Gundel U.F., Hartmann R., and Gleiter C.H. Ezetimibe and statin-associated myopathy. Ann Intern Med 20; 140 (2004) 671-672
50. Health Canada PaFB. Association of Ezetrol (ezetimibe) with myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia. Available at: http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2005/ezetrol_hpc-cps_e.html. Accessed February 6, 2006.
51. Vytorin [ezetimibe-simvastatin] prescribing information (2005), Merck/Schering-Plough, North Wales, PA. http://www.vytorin.com/vytorin/shared/documents/vytorin_pi.pdf [Vytorin Web site.] Available at: http://www.vytorin.com/vytorin/shared/documents/vytorin_pi.pdf. Accessed February 6, 2006.
52. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., Cho M., Musliner T.A., and Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1084-1091
53. Wilson R., and Shah B.R. Rhabdomyolysis. emedicine [serial online] (2004). http://www.emedicine.com/ped/topic2003.htm May 26:1-16. Available at: http://www.emedicine.com/ped/topic2003.htm.
54. Craig S. Rhabdomyolysis. emedicine (2004). http://www.emedicine.com/emerg/topic508.htm [serial online] December 29:1-15. Available at: http://www.emedicine.com/emerg/topic508.htm.
55. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La G.L., Gurwitz J.H., Chan K.A., Goodman M.J., and Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
56. Zetia [ezetimibe] prescribing information (2005), Merck/Schering-Plough, North Wales, PA. http://www.zetia.com/zetia/shared/documents/zetia_pi.pdf Available at: http://www.zetia.com/zetia/shared/documents/zetia_pi.pdf. Accessed February 6, 2006.
57. Shanahan R.L., Kerzee J.A., Sandhoff B.G., Carroll N.M., and Merenich J.A. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy 25 (2005) 345-351
58. Daugird A.J., Crowell K., and Saseen J. Clinical inquiries. Do statins cause myopathy?. J Fam Pract 52 (2003) 973-977
59. McKelvie P.A., and Dennett X. Myopathy associated with HMG-CoA reductase inhibitors (statins). a series of 10 patients and review of the literature. Journal of Clinical Neuromuscular Disease 3 (2002) 143-148
60. Chazerain P., Hayem G., Hamza S., Best C., and Ziza J.M. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 68 (2001) 430-433
61. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., and England J.D. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
62. Hunninghake D.B. Clinical efficacy of cerivastatin. phase IIa dose-ranging and dose-scheduling studies. Am J Cardiol 82 suppl 4B (1998) 26J-31J
63. Cheng-Lai A. Cerivastatin. Heart Dis 2 (2000) 93-99
64. Isaacsohn J., Insull Jr. W., Stein E., Kwiterovich P., Patrick M.A., Brazg R., Dujovne C.A., Shan M., Shugrue-Crowley E., Ripa S., and Tota R. Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol 24 suppl (2001) IV1-IV9
65. Evans E. Statin safety in perspective-maximising the risk:benefit. British Journal of Cardiology 11 (2004) 449-454
66. Rosenson R.S., and Bays H.E. Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. Am J Cardiol 1 91 (2003) 878-881
67. Xydakis A.M., and Ballantyne C.M. Combination therapy for combined dyslipidemia. Am J Cardiol 90 suppl 10B (2002) 21K-29K
68. Vega G.L. Management of atherogenic dyslipidemia of the metabolic syndrome. evolving rationale for combined drug therapy. Endocrinol Metab Clin North Am 33 (2004) 525-544 vi
69. Jones P.H. Statins as the cornerstone of drug therapy for dyslipidemia. monotherapy and combination therapy options. Am Heart J 148 suppl (2004) S9-S13
70. Covington M.B. Omega-3 fatty acids. Am Fam Physician 70 (2004) 133-140
71. Taher T.H., Dzavik V., Reteff E.M., Pearson G.J., Woloschuk B.L., and Francis G.A. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 89 (2002) 390-394
72. VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel. Statin-Fibrate Report: Focus on Safety. Available at: http://www.pbm.va.gov/safety%20reports/87ry38statin-fibrate-final.pdf. Accessed February 6, 2006.
73. Rosenson R.S. Cholesterol lowering in diabetes. new evidence supports aggressive LDL-C targets. Postgrad Med 117 (2005) 17-20 23-27
74. Bays H.E., and McGovern M.E. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 6 (2003) 179-188
75. Bays H.E., Dujovne C.A., McGovern M.E., White T.E., Kashyap M.L., Hutcheson A.G., and Crouse J.R. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 91 (2003) 667-672
76. Zhao X.Q., Morse J.S., Dowdy A.A., Heise N., DeAngelis D., Frohlich J., Chait A., Albers J.J., and Brown B.G. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93 (2004) 307-312
77. Bays H. Ezetimibe. Expert Opin Investig Drugs 11 (2002) 1587-1604
78. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94 (2004) 1140-1146
79. McKenney J.M. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health-Syst Pharm 62 (2005) 1033-1047
80. Omar M.A., and Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36 (2002) 288-295
81. Dujovne C.A., Chremos A.N., Pool J.L., Schnaper H., Bradford R.H., Shear C.L., Higgins J., Downton M., Franklin F.A., and Nash D.T. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med 91 suppl 1B (1991) 25S-30S
82. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C.A., Franklin F.A., Grillo R.B., Higgins J., Langendorfer A., Nash D.T., and Pool J.L. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. two-year efficacy and safety follow-up. Am J Cardiol 74 (1994) 667-673
83. Newman C.B., Palmer G., Silbershatz H., and Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92 (2003) 670-676
84. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
85. De A.G. The influence of statin characteristics on their safety and tolerability. Int J Clin Pract 58 (2004) 945-955
86. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
87. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E., and Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
88. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
89. Pfeffer M.A., Keech A., Sacks F.M., Cobbe S.M., Tonkin A., Byington R.P., Davis B.R., Friedman C.P., and Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials. prospective Pravastatin Pooling (PPP) Project. Circulation 105 (2002) 2341-2346
90. Davidson M.H., Stein E.A., Hunninghake D.B., Ose L., Dujovne C.A., Insull Jr. W., Bertolami M., Weiss S.R., Kastelein J.J., Scott R.S., et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day. worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 10 (2000) 253-262
91. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
92. Charles E.C., Olson K.L., Sandhoff B.G., McClure D.L., and Merenich J.A. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 118 (2005) 618-624
93. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
94. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
95. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. results of AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention Study]. JAMA 279 (1998) 1615-1622
96. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
97. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease. a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
98. US Food and Drug Administration. Response of the United States Department of Health & Human Services to Public Citizen's March 4, 2004 petition from Sidney Wolfe (2005). http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf March 11, [US Food and Drug Administration Web site.] Available at: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf. Accessed February 6, 2006
99. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., and Karas R.H. The safety of rosuvastatin as used in common clinical practice. a postmarketing analysis. Circulation 111 (2005) 3051-3057
100. Parra J.L., and Reddy K.R. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 7 (2003) 415-433
101. Heuer T., Gerards H., Pauw M., Gabbert H.E., and Reis H.E. Toxic liver damage caused by HMG-CoA reductase inhibitor [in German]. Med Klin (Munich) 95 (2000) 642-644
102. Pelli N., and Setti M. Atorvastatin as a trigger of autoimmune hepatitis [letter]. J Hepatol 40 (2004) 716
103. Graziadei I.W., Obermoser G.E., Sepp N.T., Erhart K.H., and Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12 (2003) 409-412
104. Wolters L.M., and Van Buuren H.R. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 17 (2005) 589-590
105. Pedersen T.R., and Tobert J.A. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. a reappraisal. Drug Saf 14 (1996) 11-24
106. Hartleb M., Rymarczyk G., and Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 94 (1999) 1388-1390
107. Punthakee Z., Scully L.J., Guindi M.M., and Ooi T.C. Liver fibrosis attributed to lipid lowering medications. two cases. J Intern Med 250 (2001) 249-254
108. Jimenez-Alonso J., Osorio J.M., Gutierrez-Cabello F., Lopez de la O.A., Leon L., Mediavilla Garcia J.D., and Grupo Lupus Virgen de las Nieves. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med 159 (1999) 1811-1812
109. Nakad A., Bataille L., Hamoir V., Sempoux C., and Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 353 (1999) 1763-1764
110. Caldwell S.H., Hespenheide E.E., and von Borstel R.W. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 46 (2001) 376-378
111. Bruguera M., Joya P., and Rodes J. Hepatitis associated with treatment with lovastatin. Presentation of 2 cases [in Spanish]. Gastroenterol Hepatol 21 (1998) 127-128
112. Huchzermeyer H., and Munzenmaier R. Lovastatin-induced acute cholestatic hepatitis [in German]. Dtsch Med Wochenschr 120 (1995) 252-256
113. Grimbert S., Pessayre D., Degott C., and Benhamou J.P. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 39 (1994) 2032-2033
114. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
115. de D.S., Spinler S.A., Miller K., and Peterson A.M. Statins and liver toxicity. a meta-analysis. Pharmacotherapy 24 (2004) 584-591
116. Chalasani N. Statins and hepatotoxicity. focus on patients with fatty liver. Hepatology 41 (2005) 690-695
117. Bays H., Abate N., and Chandalia M. Adiposopathy. Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology 1 (2005) 39-59
118. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 3 (2005) 393-404
119. Chitturi S., and George J. Hepatotoxicity of commonly used drugs. nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 22 (2002) 169-183
120. Mallory M.A., Lee S.W., and Kowdley K.V. Abnormal liver test results on routine screening. How to evaluate, when to refer for a biopsy. Postgrad Med 115 (2004) 53-56 59-62, 66
121. Gotto Jr. A.M. The case for over-the-counter statins. Am J Cardiol 94 (2004) 753-756
122. Downs J.R., Clearfield M., Tyroler H.A., Whitney E.J., Kruyer W., Langendorfer A., Zagrebelsky V., Weis S., Shapiro D.R., Beere P.A., and Gotto A.M. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS). additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 87 (2001) 1074-1079
123. Cressman M.D., Hoogwerf B.J., Moodie D.S., Olin J.W., and Weinstein C.E. HMG-CoA reductase inhibitors. a new approach to the management of hypercholesterolemia. Cleve Clin J Med 55 (1988) 93-100
124. Hunninghake D.B. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am 19 (1990) 345-360
125. Tolman K.G. The liver and lovastatin. Am J Cardiol 89 (2002) 1374-1380
126. Vuppalanchi R., Teal E., and Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 329 (2005) 62-65
127. Dujovne C.A. Side effects of statins. hepatitis versus "transaminitis"-myositis versus "CPKitis.". Am J Cardiol 89 (2002) 1411-1413
128. Sniderman A.D. Is there value in liver function test and creatine phosphokinase monitoring with statin use?. Am J Cardiol 94 suppl 9A (2004) 30F-34F
129. Smith C.C., Bernstein L.I., Davis R.B., Rind D.M., and Shmerling R.H. Screening for statin-related toxicity. the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 163 (2003) 688-692
130. Gotto Jr. A.M. Safety and statin therapy. reconsidering the risks and benefits. Arch Intern Med 163 (2003) 657-659
131. Agarwal R. Statin induced proteinuria. renal injury or renoprotection?. J Am Soc Nephrol 15 (2004) 2502-2503
132. Bianchi S., Bigazzi R., Caiazza A., and Campese V.M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (2003) 565-570
133. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease. a meta-analysis. Kidney Int 59 (2001) 260-269
134. Vidt D.G., Cressman M.D., Harris S., Pears J.S., and Hutchinson H.G. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102 (2004) 52-60
135. CRESTOR [rosuvastatin calcium] prescribing information (2005), AstraZeneca Pharmaceuticals LP, Wilmington, DE. http://www.astrazeneca-us.com/pi/crestor.pdf Available at: http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed August 2005.
136. US Department of Health and Human Services. US Food and Drug Administration Center for Drug Evaluation and Research, Transcript of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (2003). http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.doc July 9, [FDA Web site.] Available at: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.doc. Accessed February 6, 2006.
137. Christensen E.I. Pathophysiology of protein and vitamin handling in the proximal tubule. Nephrol Dial Transplan 17 suppl 9 (2002) 57-58
138. Sidaway J.E., Davidson R.G., McTaggart F., Orton T.C., Scott R.C., Smith G.J., and Brunskill N.J. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15 (2004) 2258-2265
139. Verhulst A., D'Haese P.C., and De Broe M.E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15 (2004) 2249-2257
140. McKenney J.M. Defining the pharmacological profile of rosuvastatin: a look at statin therapy for dyslipidemia [poster online]. France Foundation Web Site Poster: Advances in Managing Hyperlipidemia online continuing medical education activity (2005). http://www.francefoundation.com/cme/posttest/pages/amh_posters.pdf July 24, Available at: http://www.francefoundation.com/cme/posttest/pages/amh_posters.pdf. Accessed February 6, 2006
141. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., and Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
142. Bays HE. Collaborative Atorvastatin Diabetes Study (CARDS). Lipids Online Commentaries on Research 2005. Available at: http://www.lipidsonline.org. Accessed February 6, 2006.
143. US Food and Drug Administration. FDA Public Health Advisory on Crestor (rosuvastatin). Center for Drug Evaluation and Research. [FDA Web site.] Available at: http://www.fda.gov/cder/drug/advisory/crestor_3_2005.htm. Accessed February 6, 2006.
144. Amarenco P., and Tonkin A.M. Statins for stroke prevention. disappointment and hope. Circulation 109 suppl 1 (2004) III44-III49
145. Amarenco P., Lavallee P., and Touboul P.J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 3 (2004) 271-278
146. King D.S., Wilburn A.J., Wofford M.R., Harrell T.K., Lindley B.J., and Jones D.W. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23 (2003) 1663-1667
147. Orsi A., Sherman O., and Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 21 (2001) 767-769
148. Golomb B.A. Implications of statin adverse effects in the elderly. Expert Opin. Drug Saf 4 (2005) 389-397
149. Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., and Manuck S.B. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 108 (2000) 538-546
150. Muldoon M.F., Ryan C.M., Sereika S.M., Flory J.D., and Manuck S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 117 (2004) 823-829
151. Cutler N., Sramek J., Veroff A., Block G., Stauffer L., and Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol 39 (1995) 333-336
152. Harrison R.W., and Ashton C.H. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 37 (1994) 231-236
153. Yaffe K., Barrett-Connor E., Lin F., and Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59 (2002) 378-384
154. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62 (2005) 217-224
155. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen M.K., Tsuang D., van Belle G., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., and Larson E.B. Statin therapy and risk of dementia in the elderly. a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
156. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER). a randomised controlled trial. Lancet 360 (2002) 1623-1630
157. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
158. Hajjar I., Schumpert J., Hirth V., Wieland D., and Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57 (2002) M414-M418
159. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease. preliminary results. Arch Neurol 62 (2005) 753-757
160. Zamrini E., McGwin G., and Roseman J.M. Association between statin use and Alzheimer's disease. Neuroepidemiology 23 (2004) 94-98
161. Rosenson R.S., and Goranson N.L. Lovastatin-associated sleep and mood disturbances. Am J Med 95 (1993) 548-549
162. Lechleitner M., Hoppichler F., Konwalinka G., Patsch J.R., and Braunsteiner H. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin [letter]. Lancet 340 (1992) 910
163. Kassler-Taub K., Woodward T., and Markowitz J.S. Depressive symptoms and pravastatin. Lancet 341 (1993) 371-372
164. Jeppesen U., Gaist D., Smith T., and Sindrup S.H. Statins and peripheral neuropathy. Eur J Clin Pharmacol 54 (1999) 835-838
165. Jacobs M.B. Atorvastatin-induced polyneuropathy [letter]. Ann Intern Med 141 (2004) 77
166. Jacobs M.B. HMG-CoA reductase inhibitor therapy and peripheral neuropathy [letter]. Ann Intern Med 120 (1994) 970
167. Ahmad S. Lovastatin and peripheral neuropathy [letter]. Am Heart J 130 (1995) 1321
168. Phan T., McLeod J.G., Pollard J.D., Peiris O., Rohan A., and Halpern J.P. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 58 (1995) 625-628
169. Rajabally Y.A., Varakantam V., and Abbott R.J. Disorder resembling Guillain-Barre syndrome on initiation of statin therapy. Muscle Nerve 30 (2004) 663-666
170. Scola R.H., Trentin A.P., Germiniani F.M., Piovesan E.J., and Werneck L.C. Simvastatin-induced mononeuropathy multiplex. case report. Arq Neuropsiquiatr 62 (2004) 540-542
171. Corrao G., Zambon A., Bertu L., Botteri E., Leoni O., and Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy. an exploratory case-control study using automated databases. J Epidemiol Community Health 58 (2004) 1047-1051
172. Gaist D., Jeppesen U., Andersen M., Garcia Rodriguez L.A., Hallas J., and Sindrup S.H. Statins and risk of polyneuropathy. a case-control study. Neurology 58 (2002) 1333-1337
173. Gaist D., Garcia Rodriguez L.A., Huerta C., Hallas J., and Sindrup S.H. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?. Eur J Clin Pharmacol 56 (2001) 931-933
174. Backes J.M., and Howard P.A. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 37 (2003) 274-278
175. Chong P.H., Boskovich A., Stevkovic N., and Bartt R.E. Statin-associated peripheral neuropathy. review of the literature. Pharmacotherapy 24 (2004) 1194-1203
176. Golomb B.A., Kane T., and Dimsdale J.E. Severe irritability associated with statin cholesterol-lowering drugs. QJM 97 (2004) 229-235
177. Waters D. Statins and safety. applying the results of randomized trials to clinical practice. Am J Cardiol 92 (2003) 692-695
178. American Stroke Association. Impact of stroke. [American Heart Association Web site.] Available at: http://www.strokeassociation.org/presenter.jhtml?identifier=1033. Accessed February 6, 2006.
179. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke. systematic review and meta-analysis. BMJ 326 (2003) 1423-1430
180. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
181. Sparks D.L., Connor D.J., Browne P.J., Lopez J.E., and Sabbagh M.N. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 6 (2002) 324-331
182. Chong P.H., Seeger J.D., and Franklin C. Clinically relevant differences between the statins. implications for therapeutic selection. Am J Med 111 (2001) 390-400
183. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins. an update. Fundam Clin Pharmacol 19 (2005) 117-125
184. Saheki A., Terasaki T., Tamai I., and Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11 (1994) 305-311
185. Botti R.E., Triscari J., Pan H.Y., and Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 14 (1991) 256-261
186. Kikuchi R., Kusuhara H., Abe T., Endou H., and Sugiyama Y. Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J Pharmacol Exp Ther 311 (2004) 1147-1153
187. Eckernas S.A., Roos B.E., Kvidal P., Eriksson L.O., Block G.A., Neafus R.P., and Haigh J.R. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep. a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol 35 (1993) 284-289
188. Keech A.C., Armitage J.M., Wallendszus K.R., Lawson A., Hauer A.J., Parish S.E., Collins R., and Oxford Cholesterol Study Group. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Br J Clin Pharmacol 42 (1996) 483-490
189. Sano M. Current concepts in the prevention of Alzheimer's disease. CNS Spectr 8 (2003) 846-853
190. Sidera C., Parsons R., and Austen B. The regulation of beta-secretase by cholesterol and statins in Alzheimer's disease. J Neurol Sci 229 230 (2005) 269-273
191. Buxbaum J.D., Cullen E.I., and Friedhoff L.T. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci 7 (2002) a50-a59
192. Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., and Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease. a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52 (2002) 346-350
193. Cole S.L., Grudzien A., Manhart I.O., Kelly B.L., Oakley H., and Vassar R. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 280 (2005) 18755-18770
194. Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 15 (2004) 667-672
195. Crisby M., Carlson L.A., and Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 16 (2002) 131-136
196. Kirsch C., Eckert G.P., Koudinov A.R., and Muller W.E. Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36 suppl 2 (2003) S113-S119
197. Blauw G.J., ShepherdJ, Murphy M.B., and PROSPER study group. Dementia and statins. PROSPER study group [letter]. Lancet 357 (2001) 881
198. Kast R.E. Dementia and statins [letter]. Lancet 357 (2001) 881
199. Lowe G., Rumley A., Packard C., and Shepherd J. Dementia and statins [letter]. Lancet 357 (2001) 881
200. Ledesma M.D., and Dotti C.G. The conflicting role of brain cholesterol in Alzheimer's disease. lessons from the brain plasminogen system. Lipids, Rafts and Traffic. Biochemistry Society Symposia Vol. 72 (2005), Portland Press, London 129-138
201. Hartman T. Cholesterol and Alzheimer's disease. statins, cholesterol depletion in APP processing and Abeta generation. Subcell Biochem 38 (2005) 365-380
202. Algotsson A., and Winblad B. Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins. Dement Geriatr Cogn Disord 17 (2004) 109-116
203. Wagstaff L.R., Mitton M.W., Arvik B.M., and Doraiswamy P.M. Statin-associated memory loss. analysis of 60 case reports and review of the literature. Pharmacotherapy 23 (2003) 871-880
204. Etminan M., Gill S., and Samii A. The role of lipid-lowering drugs in cognitive function. a meta-analysis of observational studies. Pharmacotherapy 23 (2003) 726-730
205. Caballero J., and Nahata M. Do statins slow down Alzheimer's disease? A review. J Clin Pharm Ther 29 (2004) 209-313
206. Rockwood K., and Darvesh S. The risk of dementia in relation to statins and other lipid lowering agents. Neurol Res 25 (2003) 601-604
207. Ebrahim S., Shlomo Y.B., Smith G.D., Whincup P., and Emberson J. Dementia and statins [letter]. Lancet 357 (2001) 882
208. Golomb B.A., Criqui M.H., White H.L., and Dimsdale J.E. The UCSD Statin Study. a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 25 (2004) 178-202
209. Pascuzzi R.M. Peripheral neuropathies in clinical practice. Med Clin North Am 87 (2003) 697-724
210. Anderson J.L., Muhlestein J.B., Bair T.L., Morris S., Weaver A.N., Lappe D.L., Renlund D.G., Pearson R.R., Jensen K.R., and Horne B.D. Do statins increase the risk of idiopathic polyneuropathy?. Am J Cardiol 95 (2005) 1097-1099
211. Lo Y.L., Leoh T.H., Loh L.M., and Tan C.E. Statin therapy and small fibre neuropathy. a serial electrophysiological study. J Neurol Sci 208 (2003) 105-108
212. Donaghy M. Assessing the risk of drug-induced neurologic disorders. statins and neuropathy. Neurology 58 (2002) 1321-1322